COST-EFFECTIVENESS ANALYSIS OF BEMPEDOIC ACID AND EZETIMIBE IN COMBINATION WITH MAXIMUM TOLERATED DOSE OF STATINS (ADD ON STRATEGY) IN JORDAN
Author(s)
Farah Radaydeh, MSc1, Rawan Alfroukh, MSc1, Nimer Alkhatib, PhD2.
1Path economics,LLC, Amman, Jordan, 2College of pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
1Path economics,LLC, Amman, Jordan, 2College of pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
OBJECTIVES: To evaluate the cost-effectiveness of bempedoic acid plus ezetimibe added to maximally tolerated statins compared with statins alone and ezetimibe plus statins in a Jordanian population.
METHODS: A microsimulation model was developed using patient characteristics derived from Study 1002FDC-053 and informed by the Jordanian multidisciplinary consensus on dyslipidemia (2023). Ten-year cardiovascular disease (CVD) risk was estimated using the SCORE2 algorithm, which incorporates age, sex, smoking status, and LDL-C levels. Clinical efficacy inputs were based on phase III trial evidence. Direct medical costs were obtained from the Jordan Food and Drug Administration (JFDA) price lists. Given the limitations of applying quality-adjusted life years in this context, outcomes were expressed as a percentage reduction in the 10-year risk of fatal and non-fatal CVD. Incremental cost-effectiveness ratios (ICERs) were calculated per 1% CVD risk averted.
RESULTS: Bempedoic acid plus ezetimibe added to maximally tolerated statins reduced 10-year CVD risk by 1.7% compared with statins alone and by 1.13% compared with ezetimibe plus statins. The corresponding ICERs were Jordanian dinar (JOD) 8,716 per 1% CVD risk averted versus statins alone and JOD 9,959 per 1% CVD risk averted versus ezetimibe plus statins.
CONCLUSIONS: In Jordan, bempedoic acid plus ezetimibe as an add-on therapy provides additional cardiovascular risk reduction compared with current standard lipid-lowering strategies. These findings support its potential clinical and economic value within the national healthcare context.
METHODS: A microsimulation model was developed using patient characteristics derived from Study 1002FDC-053 and informed by the Jordanian multidisciplinary consensus on dyslipidemia (2023). Ten-year cardiovascular disease (CVD) risk was estimated using the SCORE2 algorithm, which incorporates age, sex, smoking status, and LDL-C levels. Clinical efficacy inputs were based on phase III trial evidence. Direct medical costs were obtained from the Jordan Food and Drug Administration (JFDA) price lists. Given the limitations of applying quality-adjusted life years in this context, outcomes were expressed as a percentage reduction in the 10-year risk of fatal and non-fatal CVD. Incremental cost-effectiveness ratios (ICERs) were calculated per 1% CVD risk averted.
RESULTS: Bempedoic acid plus ezetimibe added to maximally tolerated statins reduced 10-year CVD risk by 1.7% compared with statins alone and by 1.13% compared with ezetimibe plus statins. The corresponding ICERs were Jordanian dinar (JOD) 8,716 per 1% CVD risk averted versus statins alone and JOD 9,959 per 1% CVD risk averted versus ezetimibe plus statins.
CONCLUSIONS: In Jordan, bempedoic acid plus ezetimibe as an add-on therapy provides additional cardiovascular risk reduction compared with current standard lipid-lowering strategies. These findings support its potential clinical and economic value within the national healthcare context.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE175
Topic
Economic Evaluation
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), No Additional Disease & Conditions/Specialized Treatment Areas